ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

India’s Ranbaxy Halts Two Troubled Plants

by Jean-François Tremblay
March 3, 2014 | APPEARED IN VOLUME 92, ISSUE 9

Ranbaxy Laboratories has put all shipments on hold at plants producing active pharmaceutical ingredients in Toansa and Dewas, India. The firm says it voluntarily made the decision to examine processes and controls at the facilities. Products from the two sites have been banned from the U.S. since January when FDA found manufacturing deficiencies at the plants. FDA earlier banned products made at Ranbaxy’s plant in Mohali, India. Japanese drug firm Daiichi Sankyo is Ranbaxy’s majority owner.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment